ImmunityBio Faces Lawsuits Over Misleading Anktiva Claims

ImmunityBio, Inc. is facing multiple securities class action lawsuits after the United States===Food and Drug Administration issued a warning letter on March 13, 2026, which became public on March 24, 2026. The FDA asserted that ImmunityBio continued to promote its bladder-cancer drug, Anktiva, in a misleading manner, despite previous warnings. Specifically, the FDA cited claims made by ImmunityBio's executive chairman and Chief Scientific and Medical Officer, Patrick Soon-Shiong, on Sean Spicer's podcast and in television advertisements, which suggested Anktiva could treat all cancers and ensure long-term cancer-free outcomes, without sufficient supporting data. This news caused ImmunityBio's stock price to fall by over 21%, erasing nearly $2 billion in market capitalization. Law firms including Pomerantz LLP, Bronstein, Gewirtz & Grossman, LLC, Hagens Berman, Rosen Law Firm, The Schall Law Firm, Faruqi & Faruqi, LLP, and Kahn Swick & Foti, LLC are now representing investors in class action lawsuits, alleging securities fraud and that ImmunityBio made false and misleading statements about Anktiva's capabilities.